SCHEMBL19689738

SCHEMBL19689738

O=C(NCc1ccc2c(c1)CCN2)Nc1ccc(F)cc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
RAB9A P51151 4/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
NPC1 O15118 3/20 0.44
PARP1 P09874 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
F3 P13726 1/20 0.43
HTT P42858 2/20 0.43
TRPV1 Q8NER1 1/20 0.42
PKM P14618 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41
THRB P10828 1/20 0.41
DDR1 Q08345 1/20 0.41
DDR2 Q16832 1/20 0.41
PPIA P62937 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19707682 0.78 L3MBTL1 (0.52) KDM4EALDH1A1THRB
SCHEMBL19689659 0.72 MAPT (0.88) MAPTPOLB
SCHEMBL19689645 0.71 MAPT (0.73) MAPTPOLBTHRB
SCHEMBL19689633 0.71 MAPT (0.70) MAPTPOLBTHRB
SCHEMBL19708625 0.70 MAPT (0.69) MAPTPOLBTHRB
SCHEMBL549063 0.68 DRD2 (0.59) MAPTPARP1KDM4EALDH1A1HTT
SCHEMBL27193044 0.68 RAB9A (0.77) MAPTRAB9ANPC1KDM4EALDH1A1
SCHEMBL5800735 0.68 GAA (0.58) RAB9AMEN1KMT2ANPC1KDM4E
SCHEMBL25781080 0.68 IDO1 (0.51) MAPTRAB9AMEN1KMT2AHTT
SCHEMBL24449105 0.68 ALDH1A1 (0.46) MAPTRAB9AKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641881-B 1-tetrahydropyranyl carbonyl-2, 3-dihydro-1H-indole compounds for use in the treatment of cancer 伊莱利利公司 2022-01-07 CN disclosed
US-10759786-B2 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer ELI LILLY AND COMPANY (US) 2020-09-01 US disclosed
EP-3468965-B1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER LILLY CO ELI (US) 2020-04-29 EP disclosed
US-20190161477-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER ELI LILLY AND COMPANY 2019-05-30 US disclosed
EP-3468965-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER Eli Lilly and Company (US) 2019-04-17 EP disclosed
US-9872853-B2 2,3-dihydro-1H-indole compounds ELI LILLY AND COMPANY (US) 2018-01-23 US disclosed
US-20170354641-A1 2,3-DIHYDRO-1H-INDOLE COMPOUNDS ELI LILLY AND COMPANY 2017-12-14 US disclosed
WO-2017213919-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER ELI LILLY AND COMPANY (US) 2017-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161477-A1 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER MCL1, IDO1, GLI1 MAPT 3345/4885RAB9A 3450/4885MEN1 255/4885
US-10759786-B2 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer MCL1, FOXM1, IDO1 MAPT 3015/4885RAB9A 3196/4885MEN1 189/4885
US-20170354641-A1 2,3-DIHYDRO-1H-INDOLE COMPOUNDS MCL1, IDO1, IDO2 MAPT 3006/4885RAB9A 2836/4885MEN1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.